Mariner’s Y-mAbs Therapeutics YMAB Stock Holding History

Mariner’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,755	Closed	-$82K	–	2890
2022 Q4	$82K	Buy	+16,755	New	+$122K	﹤0.01%	2554

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Mariner's YMAB Position: Q1 2023 in Review

Mariner sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 16,755 shares — an estimated $82K sold.

Mariner first reported a position in YMAB in Q4 2022 and held it in 1 quarter. The position peaked at $82K in Q4 2022. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

Mariner reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
Mariner sold 16,755 Y-mAbs Therapeutics shares in Q1 2023, an estimated $82K.
Mariner first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 1 quarter.
Mariner's Y-mAbs Therapeutics position peaked at $82K in Q4 2022.
85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.